tbuckley/cabot-search huggingface dataset:
AB0726 Severe Obesity Is Frequent in Patients with Psoriatic Arthritis and Is Accompanied by Increased Cardiovascular Risk
Authors: D. Huscher, K. Albrecht, S. Bischoff, K. Thiele, F. Behrens, G. Hoese, W. Ochs, A. Zink
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> It is known that patients with psoriatic arthritis (PsA) are at increased risk of obesity and associated cardiovascular comorbidity, in particular those with severe and long-standing disease (&gt;10 years). There is less information on the frequency of obesity and cardiovascular risk in patients with incident or medium-term disease. <h3>Objectives</h3> To investigate the prevalence of obesity compared to the population, disease presentation and the cardiovascular morbidity at onset of disease and after a mean of five years disease. <h3>Methods</h3> We selected two discrete groups of patients with a PsA diagnosis (M07.0-M07.3) enrolled in the national database of the German Collaborative Arthritis Centres between 2003 and 2014: patients with either short (≤0.5 years) or longer disease duration (between 4 and 6 years). Stratified by BMI classes, disease activity and cardiovascular comorbidity, as well as the deviation of the BMI from the age- and sex-matched normal population were analysed. <h3>Results</h3> 421 patients were enrolled with incident disease (mean disease duration 3.0 months) and 965 with medium-term PsA (mean 5.0 years). Both the BMI distribution in general and the portion of patients with severe obesity (BMI≥35, ∼8%) were similar in incident and medium-term PsA. In comparison to the age- and sex-matched population, obesity was more frequent in patients with incident (23.5% vs. 16.1%) as well as in medium-term PsA (24.7% vs. 17.4%). Obesity was associated with higher disease activity, higher patient-reported burden and substantially higher prevalence of cardiovascular risk factors already in early PsA except for significantly lower smoking rates (Table1). In medium-term PsA, 23.6% of all patients (mean age 52 years) and 36.1% of the obese patients (mean age 54 years) presented with any cardiovascular risk factor (diabetes, hypertension, hypercholesterolemia or heart disease); in obese patients the prevalence of coronary heart disease (10.1%) was doubled compared to incident patients. Table 1 shows patient characteristics in incident PsA. <h3>Conclusions</h3> One quarter of the patients with PsA are obese, already at the onset of the disease, and they present with more severe obesity than the age and sex matched normal population. The high cardiovascular comorbidity at onset of PsA is further significantly increased in obese patients already after five years of disease. This should be considered in the treatment of these patients. <h3>Acknowledgement</h3> The database was funded by the German Federal Minister of Research from 1999 to 2007 (grant #01 GI 0344/3). Since 2007, the Working group of the regional collaborative arthritis centres and a consortium of pharmaceutical companies has been funding the National Database by an unconditional grant to the German Society for Rheumatology. <h3>Disclosure of Interest</h3> None declared
Expression of ZAP-70 in B Cell Chronic Lymphocytic Leukemia Is Associated with a Greater Capacity To Activate NFκB Following Ligation of Surface Immunoglobulin.
Authors: Januario E. Castro, Carlos E. Prada, Jorieth M. Jose, Scott A. Jung, Liguang J. Chen, Gabriel A. Meraz, Thomas J. Kipps
Journal: Blood (2004)
Safety and Efficacy of FLAMSA Regimen Followed by Allogeneic Hematopoietic Stem Cell Transplantation From Related and Unrelated Donors in High Risk Acute Leukemia and MDS Patients: A Study From the Societe Française De Greffe De Moelle Et De Therapie Cellulaire (SFGM-TC) Registry.
Authors: Giovanna Cannas, Anne Huynh, Stéphane Morisset, Mohamad Sobh, Nicole Raus, Frederic Garban, Catherine Cordonnier, Jacques-Olivier Bay, Jérôme Cornillon, Agnes Buzyn, Ibrahim Yakoub-Agha, Catherine Faucher, Sylvie Francois, Pierre Bordigoni, Nathalie Fegueux, Loic Fouillard, Marie Robin, Eric Deconinck, Oumédaly Reman, Nathalie Dhedin, Thierry De Revel, Bruno Lioure, Noel Milpied, Mohamad Mohty, Mauricette Michallet
Journal: Blood (2009)
Cardioprotection and lifespan extension by the natural polyamine spermidine
Authors: Tobias Eisenberg, Mahmoud Abdellatif, Sabrina Schroeder, Uwe Primessnig, Slaven Stekovic, Tobias Pendl, Alexandra Harger, Julia Schipke, Andreas Zimmermann, Albrecht Schmidt, Mingming Tong, Christoph Ruckenstuhl, Christopher Dammbrueck, Angelina S Gross, Viktoria Herbst, Christoph Magnes, Gert Trausinger, Sophie Narath, Andreas Meinitzer, Zehan Hu, Alexander Kirsch, Kathrin Eller, Didac Carmona-Gutierrez, Sabrina Büttner, Federico Pietrocola, Oskar Knittelfelder, Emilie Schrepfer, Patrick Rockenfeller, Corinna Simonini, Alexandros Rahn, Marion Horsch, Kristin Moreth, Johannes Beckers, Helmut Fuchs, Valerie Gailus-Durner, Frauke Neff, Dirk Janik, Birgit Rathkolb, Jan Rozman, Martin Hrabe de Angelis, Tarek Moustafa, Guenter Haemmerle, Manuel Mayr, Peter Willeit, Marion von Frieling-Salewsky, Burkert Pieske, Luca Scorrano, Thomas Pieber, Raimund Pechlaner, Johann Willeit, Stephan J Sigrist, Wolfgang A Linke, Christian Mühlfeld, Junichi Sadoshima, Joern Dengjel, Stefan Kiechl, Guido Kroemer, Simon Sedej, Frank Madeo
Journal: Nature Medicine (2016)
Activity of Combined Flavopiridol and Lenalidomide in Patients with Cytogenetically High Risk Chronic Lymphocytic Leukemia (CLL): Updated Results of a Phase I Trial,
Authors: Kristie A. Blum, Lai Wei, Jeffrey A. Jones, Leslie A Andritsos, Joseph M. Flynn, Nyla A. Heerema, Xiaoxia Yang, Darlene Rozewski, Mitchell Phelps, Amy J Johnson, Michael R. Grever, John C. Byrd
Journal: Blood (2011)
The Prognostic Value of YKL-40 in Allogeneic Hematopoietic Cell Transplantation
Authors: Brian Kornblit, Tao Wang, Stephanie J. Lee, Stephen R. Spellman, Xiaochun Zhu, Katharina Fleischhauer, Carlheinz Müller, Michael R. Verneris, Julia S. Johansen, Lars Vindelov, Peter Garred
Journal: Blood (2014)
Gene Expression Profiles Document That Recently- and Previously-Divided CLL Fractions Represent a Continuum but Suggest Differing Modes of Activation for These Fractions in U-CLL and M-CLL
Authors: Xiao J. Yan, Wentian Li, Sophia Yancopoulos, Igor Dozmorov, Carlo Calissano, Sonia Marsilio, Rajendra N Damle, Steven L. Allen, Jonathan E. Kolitz, Jacqueline C. Barrientos, Kanti R. Rai, Nicholas Chiorazzi
Journal: Blood (2012)
PWE-012 Maintenance Therapy with Salofalk Granules Improves Long Term Management of UC Patients in Primary Care
Authors: D Aldulaimi, H Prasher, D Farmer, R Jazrawi
Journal: Gut (2016)

<h3>Introduction</h3> Following induction of remission, the majority of patients with mild to moderate UC are on 5 ASA maintenance therapy in primary care. Lack of adherence to therapy and patient acceptance of poorer life quality lead to disease relapse, increased severity and complication which impact NHS resources. Our aim was to evaluate the effect of changing to once daily (OD) Salofalk Granules in patients inadequately controlled on their current 5 ASA therapy. <h3>Methods</h3> UC patients on 5 ASA therapy from 31 practices covering three CCGs were invited to attend a clinic at their practice. Disease activity (Walmsley Index, use of steroids, days off work and GP and hospital visits were assessed in the past 6 months. A subgroup was switched to Salofalk Granules OD maintenance therapy (main reasons tablet load and dosing frequency 65% and symptoms 29%). All parameters were reassessed 6 months later. <h3>Results</h3> 158 patients had two complete assessments (99 stayed on current 5 ASA, 59 switched to Salofalk Granules) There was no difference in age, M:F ratio or UC subclass between the two groups. Patients changing to Salofalk Granules had a higher baseline Walmsley Index (2.78 vs 1.99; p &lt; 0.01). On reassessment, in patients changed to Salofalk Granules there was a significant reduction in Walmsley Index 2.78 to 2.02, (p &lt; 0.0001) vs. 1.99 to 2.01 (NS); more patients felt better (30/59 vs 3/99), fewer felt worse (1/59 vs. 8/99); Patients on Salofalk Granules also had 44% fewer GP visits, 87% fewer hospital visits, 86% fewer days off work and 56% fewer steroid courses. There was an annualised cost saving of £27,500 <h3>Conclusion</h3> In UC inadequately controlled on current 5 ASAs, changing to OD Salofalk Granules improved overall quality of care by improving disease outcomes, patient quality of life, reducing use of NHS resources and cost. <h3>Disclosure of Interest</h3> D. Aldulaimi: None Declared, H. Prasher: None Declared, D. Farmer: None Declared, R. Jazrawi Conflict with: Dr R Jazrawi is medical Director of Dr Falk Pharma UK
A Comparison of Apheresis Cell Content Collected from the Same Donors Mobilized with Granulocyte Colony Stimulating Factor (G-CSF) Vs. a Single Injection of AMD3100.
Authors: Sakti Chakrabarti, Y. Takahashi, E.J. Read, H. Khuu, R. Goodwin, S. Leitman, C. D. Bolan, R. Srinivasan, A.J. Barrett, G. Calandra, R. Childs
Journal: Blood (2004)
Successful Gene Therapy of Murine Paroxysmal Nocturnal Hemoglobinuria (PNH) Using Mgmt-Mediated In Vivo Selection of Genetically Corrected, Drug-Resistant Hematopoietic Stem Cells.
Authors: François Moreau-Gaudry, Bing Han, Emmanuel Richard, Ike E. Pantazopoulos, Hubert de Verneuil, Monica Bessler
Journal: Blood (2004)
Complex Aberrant Karyotypes and Unbalanced Translocations in CLL Correlate with an Unmutated IgVH Status: A Study on 133 Patients Studied with Chromosome Banding Analysis, Interphase FISH, IgVH Mutation Status, ZAP-70 RNA Expression and Immunophenotyping.
Authors: Frank Dicker, Susanne Schnittger, Wolfgang Kern, Torsten Haferlach, Claudia Schoch
Journal: Blood (2005)
Functional Modulation of VLA6 in BCR-ABL1+ Pre-B Acute Lymphoblastic Leukemia.
Authors: Eun Ji Gang, Yao-Te Hsieh, Huimin Geng, Jennifer Pham, Markus Muschen, Adele de Arcangelis, Cheryl L Willman, William L. Carroll, Elisabeth Georges-Labouesse, Halvard Bonig, Yong-Mi Kim
Journal: Blood (2012)
Profound Shut-Down of Antigen Specific T-Cell Effector Functions by Dasatinib.
Authors: Ralf Weichsel, Carolin Dix, Linda Wooldrige, Matthew Clement, Angharad Fenton-May, Josef Zezula, Elisabeth Greiner, Emma Gostick, David A. Price, Hermann Einsele, Ruth Seggewiss
Journal: Blood (2007)
Direct Suppression of Fas-Mediated Apoptosis by PMLRARa through Forming An Apoptotic Inhibitory Complex with c-FLIP In Acute Promyelocytic Leukemia
Authors: Rong-Hua Tao, Zuzana Berkova, Jillian F Wise, Daniluk Urszula, Li Bai, Xue Ao, Felipe Samaniego
Journal: Blood (2010)
Under Affordable Care Act, Uninsured Rates Fell Across Demographic Groups
Authors: Jennifer Abbasi
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Recent Advances of Light-Mediated Theranostics
Authors: Xiangzhao Ai, Jing Mu, Bengang Xing
Journal: Theranostics (2016)

Currently, precision theranostics have been extensively demanded for the effective treatment of various human diseases.Currently, efficient therapy at the targeted disease areas still remains challenging since most available drug molecules lack of selectivity to the pathological sites.Among different approaches, light-mediated therapeutic strategy has recently emerged as a promising and powerful tool to precisely control the activation of therapeutic reagents and imaging probes in vitro and in vivo, mostly attributed to its unique properties including minimally invasive capability and highly spatiotemporal resolution.Although it has achieved initial success, the conventional strategies for light-mediated theranostics are mostly based on the light with short wavelength (e.g., UV or visible light), which may usually suffer from several undesired drawbacks, such as limited tissue penetration depth, unavoidable light absorption/scattering and potential phototoxicity to healthy tissues, etc.Therefore, a near-infrared (NIR) light-mediated approach on the basis of long-wavelength light (700-1000 nm) irradiation, which displays deep-tissue penetration, minimized photo-damage and low autofluoresence in living systems, has been proposed as an inspiring alternative for precisely phototherapeutic applications in the last decades.Despite numerous NIR light-responsive molecules have been currently proposed for clinical applications, several inherent drawbacks, such as troublesome synthetic procedures, low water solubility and limited accumulation abilities in targeted areas, heavily restrict their applications in deep-tissue therapeutic and imaging studies.Thanks to the amazing properties of several nanomaterials with large extinction coefficient in the NIR region, the construction of NIR light responsive nanoplatforms with multifunctions have become promising approaches for deep-seated diseases diagnosis and therapy.In this review, we summarized various light-triggered theranostic strategies and introduced their great advances in biomedical applications in recent years.Moreover, some other promising light-assisted techniques, such as photoacoustic and Cerenkov radiation, were also systemically discussed.Finally, the potential challenges and future perspectives for light-mediated deep-tissue diagnosis and therapeutics were proposed.
The Proliferation Inhibitor CDKN1C (P57KIP2) Is Over Expressed in CD34+ Cells of Patients with MDS and Determines a Worse Prognosis Independently of IPSS Score Factors
Authors: Sascha Dietrich, Mindaugas Andrulis, Andrea Pellagatti, Aleksandar Radujkovic, Ulrich Germing, Stephan Baldus, Thomas Giese, Jacqueline Boultwood, Peter H Krammer, Peter Dreger, Anthony D. Ho, Thomas Luft
Journal: Blood (2012)
Novel Gene Delivery System of Sendai Virus Transduced Human Peripheral Monocytes.
Authors: Tomoko Tanaka, Ryo Kurita, Kashiya Takasugi, Takafumi Nakamura, Makoto Inoue, Mamoru Hasegawa, Fumiko Ono, Keiji Terao, Yasuhiro Yoshikawa, Kenzaburo Tani
Journal: Blood (2006)
ThoC1 is required for early embryonic development in the mouse
Authors: Xiaoling Wang, David Goodrich
Journal: Cancer Research (2006)

2525   The yeast TREX complex physically couples the elongating RNA polymerase II machinery with RNA processing and nuclear export factors thereby facilitating efficient and regulated gene expression. Hpr1p is an essential component of TREX, and loss of Hpr1p compromises transcriptional elongation, RNA export, and genome stability. Despite these defects, Hpr1p deficiency is not lethal in yeast. Functional orthologues of Hpr1p have been identified in metazoan species including mammals and insects (alternately known as  Thoc1 , Hpr1, or p84), but their physiological functions have not been determined. Here we describe the generation and phenotypic characterization of mice containing a null allele of the mouse  Thoc1  gene. Heterozygous null  Thoc1  mice are born at the expected Mendelian frequency with no phenotype distinguishable from wild type. In contrast, homozygous null mice are not recovered, indicating  Thoc1  is required for embryonic development. Embryonic development is arrested around the time of implantation as blastocysts exhibit hatching and blastocyst outgrowth defects upon in vitro culture. Cells of the inner cell mass are particularly dependent on  Thoc1  as these cells rapidly lose viability coincident with  Thoc1  protein loss. While Hpr1p is not essential for the viability of unicellular yeasts, the mammalian orthologue  Thoc1  is required for viability of the mammalian embryo.
Abstract 14568: Clinical Indirect Indicators of Hemodynamics Do Not Accurately Reflect Systemic Oxygen Transport Status in Neonates After the Norwood Procedure
Authors: Xiaoyang Yu, Gensheng Zhang, Sally Cai, Jia Li
Journal: Circulation (2011)

Objectives: Indirect indicators of hemodynamics (heart rate (HR), systolic (SAP) and diastolic (DAP) arterial pressures, arterial (SaO2) and venous (SvO2) O2 saturations) are commonly used to guild...
PTU-156 Assessing Current UK Practice for Endoscopic Surveillance in Achalasia
Authors: R Sinha, A Wyman, H Ellison, C O’Shea, M Bramble
Journal: Gut (2016)

<h3>Introduction</h3> There are no established guidelines on achalasia surveillance from the British Society of Gastroenterology(BSG)or the American Society for Gastrointestinal Endoscopy(ASGE).In the absence of guidance,conflicting evidence<sup>1,2 </sup> and lack of consensus amongst global experts,<sup>3</sup>a varied clinical practice prevails in the UK.The aim of this study was to document current clinical practice among UK endoscopists regarding achalasia surveillance. <h3>Methods</h3> An online survey was conducted using SurveyMonkey<b>®</b> endorsed by BSG,AUGIS(Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland)and JAG(Joint Advisory Group on GI Endoscopy).The link was emailed to all the registered members.The first round was conducted in March2015 with a reminder later in August2015. <h3>Results</h3> The response rate was 71% inclusive of both rounds.Overall 80%of respondents had been performing gastroscopy for over a decade and 68%declared an interest in achalasia and upper gastrointestinal cancer.Almost all(98%)had either diagnosed or performed gastroscopy in patients with achalasia and 62%performed biopsy but only if there was a macroscopic lesion at the time of the index gastroscopy.22%of the respondents performed routine random biopsy of distal oesophagus but only 1.3%used lugol’s iodine to target biopsies.Despite the high levels of interest,79%of the respondents did not undertake cancer surveillance in achalasia.Of those who did, less than a quarter(21%)proposed surveillance either after a fixed duration of diagnosis or completion of treatment; majority (80%)proposing a surveillance gastroscopy every 2–3 years whilst 18%recommended every 5 years.Most (58%)performed endoscopic inspection for a macroscopic lesion;26%performed random distal biopsies and 16% used lugol’s iodine during surveillance. 93%of respondents had no anecdotal experience of malignancy arising on a background of previously diagnosed achalasia. <h3>Conclusion</h3> The majority of specialists do not endorse cancer surveillance in achalasia based on a very low perceived risk and anecdotal experience.There is a need for establishing a national database to study the natural history,long-term management and cost-effectiveness of surveillance.It would be helpful for the BSG to recommend against surveillance,highlighting the lack of sufficient evidence and enthusiasm as judged by current clinical practice. <h3>References</h3> 1 LeeuwenburghI, <i>et al</i>. Long-term esophageal cancer risk in patients with primary achalasia:a prospective study.<i>Am J Gastroenterol</i> 2010:2144–2149. 2 Brucher BL, <i>et al</i>. Achalasia and esophageal cancer: incidence, prevalence and prognosis. <i>World J Surg</i> 2001:745–749. 3 Ravi K, <i>et al</i>. Esophageal Cancer screening in Achalasia: Is there a consensus? <i>Gastroenterology</i> 2014;146S–682. <h3>Disclosure of Interest</h3> None Declared
NTCT-08STEREOTACTIC RADIOSURGERY (SRS) FOR SPINAL METASTASES: A COMPLICATION PROFILE OF VERTEBRAL BODY FRACTURE. ANALYSIS OF 79 CASES
Authors: Shimony Nir, Jonash Tali, Benjamin W. Corn, Diana Matceyevsky, Elijahu Gez, Natan Shtraus, Zvi Lidar, Andrew A. Kanner
Journal: Neuro-Oncology (2015)

Radiation treatment of spinal and paraspinal tumors has been limited by the tolerance of the spinal cord. Radiosurgery uses a stereotactic approach to deliver a conformal, high radiation dose to a localized target thereby increasing the likelihood of successful tumor control while minimizing radiation damage to the spinal cord. Since the first description of LINAC-based spinal SRS, multiple centers have reported their experience with emphasis on tumor and pain control. Recently reports on side effects and complications, including myelopathy and vertebral body fractures, were published. In this study, we summarize the risk of developing vertebral body fractures after the use of SRS for spinal metastases. This is a (IRB-approved) retrospective review of patients with metastatic lesions, who were treated with SRS between November 2007 and October 2014 in our institution. We performed a neuro-radiological imaging review and compared data sets before and after the treatment. Patients were grouped for pre-existing and newly developed vertebral fracture occurring after the SRS treatment. 79 patients were treated by SRS for spinal metastases during the study period; we collected data for 67 spinal segments with sufficient follow up data. Mean age was 61 years (25-80 years). Distribution according to spinal segments: cervical (8.7%), thoracic (40.6%), lumbar (43.5%) and sacral (7.2%). Mean prescription dose: 17.52Gy (8-25Gy) in mean 1.7(1-5) fractions. Mean maximal dose was 21.56Gy and mean peripheral dose was 15.51Gy.We noted new vertebral fracture in 18 cases (26.1%), mean time for follow up imaging 5 months (±7.1months). No patient was symptomatic from the fracture or needed a spinal fixation. The overall mean survival was 25.86 months (±19.83months). Spinal SRS is an effective palliative procedure with a low morbidity profile. Yet spinal fractures occur after the radiation treatment relatively commonly and patients therefore require active surveillance for this side effect.
Acute Myelogenous Leukemia Blasts Contribute to a Bone Marrow-Stroma in In Vivo NOD/SCID Mouse System..
Authors: Haruko Tashiro, Ryosuke Shirasaki, Yoko Oka, Toshihiko Sugao, Nobu Akiyama, Kazuo Kawasugi, Naoki Shirafuji
Journal: Blood (2009)
Improvement of Hematopoietic and Stromal Cells Interaction after PTH Treatment of Long-Term Bone Marrow Cultures from Patients with Aplastic Anemia.
Authors: Tatiana V. Petrova, Irina N. Nifontova, Daria A. Svinareva, Maria A. Vinogradova, Elena A. Michaylova, Nina J. Drize
Journal: Blood (2006)
Propensity Score Matched Comparison of Dasatinib and Nilotinib As a Frontline Therapy in Newly Diagnosed CML with Chronic Phase
Authors: Koichi Takahashi, Hagop M. Kantarjian, Preetesh Jain, Elias Jabbour, William Wierda, Naveen Pemmaraju, Alessandra Ferrajoli, Sara E Dellasala, Sherry Pierce, Srdan Verstovsek, Farhad Ravandi, Susan O'Brien, Jorge E. Cortes
Journal: Blood (2014)
Evaluation of Single-Dose Palifermin To Reduce Oral Mucositis (OM) in Fractionated Total Body Irradiation (fTBI) and High Dose (HD) Chemotherapy with Autologous Peripheral Blood Progenitor Cell (PBPC) Transplantation.
Authors: Thomas C. Shea, Tarun Kewalramani, Yong Mun, Gerald Jayne, Lyndah K. Dreiling
Journal: Blood (2006)
Mimicking Myeloma Niche Ex Vivo
Authors: Jana Jakubikova, Danka Cholujova, Richard W Groen, Jungnam Joo, Sun-Young Kong, Teru Hideshima, Rikio Suzuki, Jan Sedlak, Constantine S Mitsiades, David M Dorfman, Jacob P. Laubach, Nikhil C. Munshi, Paul G. Richardson, Kenneth Anderson
Journal: Blood (2014)